链激酶可激活体内纤溶系,使纤维蛋白溶酶原转化为纤维蛋白溶酶,从而产生纤溶效果。全身应用链激酶最担心的并发症是出血,这一倾向较传统的抗凝药为重。但局部动脉内应用链激酶的用量仅为3000～10000u/h,较常规全身用量小10～30倍,似可减少出血的发生率或出血的严重性。本文对急性动脉阻塞13例局部应用小剂量链激酶进行临床观察。 Streptokinase activates fibrinolysis in the body and renders plasminogen into plasmin, resulting in a fibrinolytic effect. The most common complication of systemic streptokinase is bleeding, a trend that is more prevalent than the more traditional anticoagulants. However, the use of local arterial streptokinase only 3000 ~ 10000u / h, 10 ~ 30 times smaller than the conventional systemic dosage, it may reduce the incidence of bleeding or the severity of bleeding. In this paper, acute arterial occlusion in 13 cases of local application of low-dose streptokinase for clinical observation.